688331 荣昌生物
已收盘 01-12 15:00:01
资讯
新帖
简况
荣昌生物与艾伯维达成独家许可协议 最高可获50亿美元里程碑付款
美股速递 · 20:59
荣昌生物与艾伯维达成独家许可协议 最高可获50亿美元里程碑付款
荣昌生物(09995)与艾伯维就RC148签署独家授权许可协议
智通财经 · 20:54
荣昌生物(09995)与艾伯维就RC148签署独家授权许可协议
艾伯维与荣昌生物达成协议 后者有望获得高达49.5亿美元里程碑款项
美股速递 · 20:33
艾伯维与荣昌生物达成协议 后者有望获得高达49.5亿美元里程碑款项
【券商聚焦】海通国际：市场对2026年创新药产业链情绪偏积极 看好荣昌生物等
金吾财讯 · 15:45
【券商聚焦】海通国际：市场对2026年创新药产业链情绪偏积极 看好荣昌生物等
每周股票复盘：荣昌生物（688331）拟回购股份金额不低于2000万元
证券之星 · 01-11 04:14
每周股票复盘：荣昌生物（688331）拟回购股份金额不低于2000万元
港股创新药板块尾盘持续拉升，荣昌生物涨超13%
每日经济新闻 · 01-07
港股创新药板块尾盘持续拉升，荣昌生物涨超13%
港股异动 | 荣昌生物(09995)涨超11% 机构指其处于商业化能力加速兑现通道
智通财经 · 01-07
港股异动 | 荣昌生物(09995)涨超11% 机构指其处于商业化能力加速兑现通道
荣昌生物(09995)截至12月末尚未开始股份回购
智通财经 · 01-05
荣昌生物(09995)截至12月末尚未开始股份回购
科网股分化，快手涨超11%，汽车股下挫，蔚来跌近6%
21世纪经济报道 · 01-05
科网股分化，快手涨超11%，汽车股下挫，蔚来跌近6%
港股荣昌生物午后涨近8%
每日经济新闻 · 01-05
港股荣昌生物午后涨近8%
港股异动 | 荣昌生物(09995)午后涨近8% 维迪西妥单抗新适应症拟纳入突破性疗法
智通财经 · 01-05
港股异动 | 荣昌生物(09995)午后涨近8% 维迪西妥单抗新适应症拟纳入突破性疗法
荣昌生物（688331）披露2022年及2023年A股限制性股票激励计划归属条件成就公告，12月29日股价下跌0.48%
证券之星 · 2025-12-29
荣昌生物（688331）披露2022年及2023年A股限制性股票激励计划归属条件成就公告，12月29日股价下跌0.48%
每周股票复盘：荣昌生物（688331）拟回购2000万至4000万元股份
证券之星 · 2025-12-28
每周股票复盘：荣昌生物（688331）拟回购2000万至4000万元股份
光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事
时代周报 · 2025-12-25
光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事
荣昌生物(09995.HK)涨超3%
每日经济新闻 · 2025-12-23
荣昌生物(09995.HK)涨超3%
港股异动 | 荣昌生物(09995)涨超3% 自研RC148实现双路径突破 机构看好后续临床潜力
智通财经 · 2025-12-23
港股异动 | 荣昌生物(09995)涨超3% 自研RC148实现双路径突破 机构看好后续临床潜力
荣昌生物拟回购 金额2000万元至4000万元
财中社 · 2025-12-22
荣昌生物拟回购 金额2000万元至4000万元
获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？
时代财经 · 2025-12-22
获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？
荣昌生物：关于取得金融机构股票回购专项贷款承诺函的公告
证券日报 · 2025-12-18
荣昌生物：关于取得金融机构股票回购专项贷款承诺函的公告
荣昌生物：第二届董事会第三十二次会议决议公告
证券日报 · 2025-12-15
荣昌生物：第二届董事会第三十二次会议决议公告
加载更多
公司概况
公司名称：
荣昌生物制药(烟台)股份有限公司
所属行业：
医药制造业
上市日期：
2022-03-31
主营业务：
荣昌生物制药(烟台)股份有限公司的主营业务是抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物的研发、生产和销售。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC88、RC148、RC278、RC288。泰它西普发明专利先后获得中国、美国、欧洲等国家和地区的授权，得到了国家“十一五”、“十二五”、“十三五”期间“重大新药创制”科技重大专项支持。
发行价格：
48.00
{"stockData":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":95.38,"timestamp":1768201201000,"preClose":96.96,"halted":0,"volume":6956295,"delay":0,"changeRate":-0.0163,"floatShares":162000000,"shares":564000000,"eps":-1.6811,"marketStatus":"已收盘","change":-1.58,"latestTime":"01-12 15:00:01","open":95.7,"high":96.88,"low":93,"amount":660000000,"amplitude":0.04,"askPrice":95.38,"askSize":1,"bidPrice":95.36,"bidSize":98,"shortable":0,"etf":0,"ttmEps":-1.6811,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768267800000},"marketStatusCode":5,"adr":0,"adjPreClose":96.96,"symbolType":"stock_kcb","openAndCloseTimeList":[[1768181400000,1768188600000],[1768194000000,1768201200000]],"highLimit":106.66,"lowLimit":87.26,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":563710243,"isCdr":false,"pbRate":23.17,"roa":"--","roe":"--","epsLYR":-2.73,"committee":0.133971,"marketValue":53767000000,"turnoverRate":0.0429,"status":1,"afterMarket":{"amount":0,"volume":0,"close":95.38,"buyVolume":322,"sellVolume":0,"time":1768203237558,"indexStatus":"已收盘 01-12 15:30:00","preClose":96.96},"hkstockBrief":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":92.8,"timestamp":1768205310006,"preClose":94.65,"halted":0,"volume":3228502,"delay":0,"premium":"-13.10"},"floatMarketCap":15483000000},"requestUrl":"/m/hq/s/688331","defaultTab":"news","newsList":[{"id":"1172926155","title":"荣昌生物与艾伯维达成独家许可协议 最高可获50亿美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1172926155","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172926155?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:59","pubTimestamp":1768222756,"startTime":"0","endTime":"0","summary":"荣昌生物宣布与跨国药企艾伯维签署独家许可协议。根据协议条款，荣昌生物有资格获得累计最高达50亿美元的里程碑付款。此次合作涉及特定创新药物的全球商业化权益，标志着中国生物科技企业在国际授权交易领域取得重大突破。协议具体覆盖的治疗领域及阶段性付款细节尚未披露，但业内人士指出，这笔交易规模创下中国生物科技企业对外授权的新纪录。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","688331","BK0239","LU1064130708.USD","LU1064131003.USD","LU2148510915.USD"],"gpt_icon":0},{"id":"2602517177","title":"荣昌生物(09995)与艾伯维就RC148签署独家授权许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2602517177","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602517177?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:54","pubTimestamp":1768222464,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(09995)发布公告，于2026年1月12日，公司与艾伯维集团控股公司(艾伯维)就RC148签署独家授权许可协议。RC148是公司研发的一款新型靶向PD-1/VEGF的双特异性抗体药物。根据协议，艾伯维将获得RC148在大中华区以外地区的的开发、生产和商业化的独家权利。协议经相关监管批准生效后，公司将收到6.5亿美元的首付款，并有资格获得最高达49.5亿美元的开发、监管和商业化里程碑付款，以及在大中华区以外地区净销售额的两位数分级特许权使用费。协议中所约定的里程碑付款需要满足一定的条件，公司最终可实现的里程碑付款金额尚存在不确定性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391856.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1969619763.USD","09995","BK1574","LU2148510915.USD","688331","BK0239","BK1583","LU1064130708.USD","LU1064131003.USD","BK1161","LU2488822045.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"1107559382","title":"艾伯维与荣昌生物达成协议 后者有望获得高达49.5亿美元里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1107559382","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107559382?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:33","pubTimestamp":1768221217,"startTime":"0","endTime":"0","summary":"根据最新合作协议，荣昌生物（Remegen）有资格从艾伯维（AbbVie）获得累计最高达49.5亿美元的款项。这笔巨额资金将涵盖药物研发、监管审批及商业化等多个阶段的里程碑奖励。\n该合作凸显了国际制药巨头对中国生物科技企业创新能力的认可。分段式的付款机制既保障了研发进程的可控性，也为双方创造了共赢的商业前景。随着合作项目的推进，荣昌生物有望通过达成特定技术指标和销售目标激活相应阶段的付款。\n此次交易金额创下中国生物科技企业对外授权合作的新纪录，预示着国内创新药企在全球医药产业链中的地位正在快速提升。双方未透露具体适应症细节，但市场预期该合作可能涉及肿瘤或自身免疫疾病领域的前沿疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509010.AUD","LU0432979614.USD","LU0256863811.USD","BK4585","LU0310799852.SGD","LU2129689514.USD","LU2089284900.SGD","LU0456855351.SGD","LU1003077747.HKD","LU1064131003.USD","SG9999015952.SGD","LU0661504455.SGD","SG9999003800.SGD","LU1585245621.USD","LU2237443465.HKD","LU0861579265.USD","IE0002270589.USD","LU2237443382.USD","LU0820561818.USD","IE00BFTCPJ56.SGD","LU1732800096.USD","LU1839511570.USD","IE00BN8TJ469.HKD","LU0198837287.USD","LU0098860793.USD","LU0203345920.USD","IE00BBT3K403.USD","LU0965509283.SGD","LU0689626769.HKD","LU1057294990.SGD","LU1551013425.SGD","LU0965508806.USD","LU0553294199.USD","BK4588","LU0114720955.EUR","LU0256863902.USD","LU1929549753.HKD","LU1551013342.USD","LU2148510915.USD","LU0029864427.USD","IE00B42XCP33.USD","LU1267930573.SGD","LU0170899867.USD","LU1023059063.AUD","IE00BJT1NW94.SGD","LU0289739699.SGD","LU0795875169.SGD","LU0708994859.HKD","IE00BJJMRZ35.SGD","LU2129689431.USD","LU0738911758.USD","IE00BSNM7G36.USD","LU1983299246.USD","LU0985320562.USD","LU1093756168.USD","LU2237443895.HKD","LU1430594728.SGD","LU1037948897.HKD","LU0965509101.SGD","LU2087621335.USD","BK4139","LU1291159041.SGD","LU1267930490.SGD","LU1244550577.SGD","LU2488822045.USD","LU1989771016.USD","LU1162221912.USD","IE00B19Z3581.USD","LU1093756325.SGD","LU1037948541.HKD","LU1989772923.USD","LU2089283258.USD","LU0124676726.USD","LU0943347566.SGD","LU0058720904.USD","SG9999015986.USD","IE00BVYPNV92.GBP","BK0239","LU2023251221.USD","LU0234572021.USD","LU1934455863.HKD","IE0002141913.USD","LU0545039389.USD","IE00B3PB1722.GBP","SG9999015945.SGD","BK4533","IE00B2B36J28.USD","BK4566","LU2468319806.SGD","SG9999011175.SGD","LU1718418525.SGD","LU0211328371.USD","IE00B19Z3B42.SGD","SG9999015978.USD","LU0128525929.USD","LU2089984988.USD","LU0912757837.SGD","LU0689472784.USD","LU0158827948.USD","LU2237443549.SGD","LU0211327993.USD","LU0234570918.USD","LU0949170772.SGD","IE00BLSP4239.USD","LU0320765646.SGD","LU0820561909.HKD","LU2237443978.SGD","LU1074936037.SGD","BK4581","LU1244550494.USD","LU1061106388.HKD","IE00BGHQF631.EUR","LU2112291526.USD","IE0004445239.USD","ABBV","LU0122379950.USD","SG9999001440.SGD","LU0882574055.USD","IE00BLSP4452.SGD","LU1064130708.USD","LU2129689605.HKD","IE00BDGV0183.EUR","BK4534","688331","LU1732799900.SGD","BK4559","LU1934455194.USD","LU2133065610.SGD","BK4550","LU0795875086.SGD","LU1496350502.SGD","LU0417517546.SGD","LU1989772840.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","LU1934455277.USD","LU2347655156.SGD","LU0203347892.USD","LU2237443622.USD","LU1244550221.USD","LU0310800379.SGD","LU1496350171.SGD","IE00BVYPNW00.USD"],"gpt_icon":0},{"id":"2602659414","title":"【券商聚焦】海通国际：市场对2026年创新药产业链情绪偏积极 看好荣昌生物等","url":"https://stock-news.laohu8.com/highlight/detail?id=2602659414","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602659414?lang=zh_cn&edition=full","pubTime":"2026-01-12 15:45","pubTimestamp":1768203955,"startTime":"0","endTime":"0","summary":"金吾财讯 | 海通国际研报指出，上周恒生医疗保健指数上涨10.3%，跑赢恒生指数10.7个百分点。2026年年初以来，恒生医疗保健指数涨幅为12.4%，跑赢恒生指数10.0个百分点。该机构指出，上周部分细分板块龙头显著反弹，主要归因于：一方面，前期获利了结资金影响逐步出清；另一方面，市场对2026年创新药产业链情绪偏积极，看好管线优质和推进速度快、有BD潜力、股价位置合理的板块龙头，如荣昌生物、映恩生物等。同时，受到AI主题热度高涨影响，AI医疗概念走强，高增速、业绩兑现度高的主题标的医脉通、平安好医生涨幅明显。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973039","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1615","BK0239","06978","LU1969619763.USD","LU1064131003.USD","LU1046422090.SGD","BK1587","LU1235295612.USD","BK1571","BK1617","BK1583","09995","LU2543165471.USD","HK0000252160.HKD","01833","LU2148510915.USD","09606","159992","02192","BK1142","LU2488822045.USD","BK1515","LU0049112450.USD","BK1189","LU1064130708.USD","BK1161","HK0000252152.HKD","BK1219","HK0000500386.USD","LU2328871848.SGD","BK1247","688331"],"gpt_icon":0},{"id":"2602753679","title":"每周股票复盘：荣昌生物（688331）拟回购股份金额不低于2000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602753679","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602753679?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:14","pubTimestamp":1768076051,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，荣昌生物报收于96.96元，较上周的77.79元上涨24.64%。本周，荣昌生物1月9日盘中最高价报98.0元。荣昌生物当前最新总市值546.57亿元，在生物制品板块市值排名2/51，在两市A股市值排名365/5182。本周关注点公司公告汇总：荣昌生物拟使用自有资金回购股份，金额不低于2000万元且不超过4000万元。截至2025年12月31日，公司尚未开始回购股份，后续将根据市场情况择机实施回购，并按规定履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001406.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2488822045.USD","BK1574","LU1969619763.USD","09995","BK1583","LU1064131003.USD","LU2148510915.USD","LU2328871848.SGD","BK0239","LU1064130708.USD","688331","BK1161"],"gpt_icon":0},{"id":"2601482765","title":"港股创新药板块尾盘持续拉升，荣昌生物涨超13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601482765","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601482765?lang=zh_cn&edition=full","pubTime":"2026-01-07 15:23","pubTimestamp":1767770639,"startTime":"0","endTime":"0","summary":"每经AI快讯，1月7日，港股创新药板块尾盘持续拉升，荣昌生物涨超13%，泰格医药、凯莱英涨超9%，药明生物、信达生物涨超5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601073611419537.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601073611419537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK0239","LU1064130708.USD","LU2328871848.SGD","LU2148510915.USD","09995","LU1969619763.USD","LU1064131003.USD","159992","LU2488822045.USD","688331","BK1161","06978","BK1574"],"gpt_icon":0},{"id":"2601229188","title":"港股异动 | 荣昌生物(09995)涨超11% 机构指其处于商业化能力加速兑现通道","url":"https://stock-news.laohu8.com/highlight/detail?id=2601229188","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601229188?lang=zh_cn&edition=full","pubTime":"2026-01-07 14:57","pubTimestamp":1767769043,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物涨超11%，截至发稿，涨11.02%，报90.15港元，成交额5.77亿港元。中泰证券此前指，荣昌生物正处在商业化能力加速兑现的通道上，通过高效的运营和精准的投入，公司正快速向盈亏平衡点靠拢。此前维迪西妥单抗已经有3次纳入突破性治疗，若是此次通过公示，将成为该药物的第4次突破性疗法认定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389756.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","LU1969619763.USD","LU2148510915.USD","LU1064131003.USD","LU1064130708.USD","LU2328871848.SGD","BK1574","LU2488822045.USD","688331","09995","BK0239","BK1161"],"gpt_icon":0},{"id":"2601832648","title":"荣昌生物(09995)截至12月末尚未开始股份回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2601832648","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601832648?lang=zh_cn&edition=full","pubTime":"2026-01-05 19:31","pubTimestamp":1767612664,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(09995)发布公告，截至2025年12月31日，公司尚未开始股份回购。公司将在回购期限内根据市场情况择机实施回购，并根据回购股份事项进展情况及时履行信息披露义务，上述回购进展符合法律法规的规定及公司回购方案的要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LU1064130708.USD","688331","LU2148510915.USD","LU2488822045.USD","BK1574","09995","LU1969619763.USD","BK1161","LU1064131003.USD","BK1583","LU2328871848.SGD"],"gpt_icon":0},{"id":"2601002347","title":"科网股分化，快手涨超11%，汽车股下挫，蔚来跌近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601002347","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601002347?lang=zh_cn&edition=full","pubTime":"2026-01-05 17:18","pubTimestamp":1767604739,"startTime":"0","endTime":"0","summary":"继上周五大涨迎来开门红后，港股三大指数今日呈现窄幅震荡行情，截至收盘，恒生指数微幅上涨0.03%，国企指数跌0.22%，恒生科技指数微涨0.09%。科网股走势分化，快手涨超11%，哔哩哔哩涨超4%，阿里巴巴涨超2%，网易、小米跌超2%。港股汽车股跌幅居前，蔚来跌近6%，小鹏汽车跌超4%、零跑汽车跌超3%，长城汽车跌超6%。生物医药股涨幅居前，荣昌生物涨超7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601053608889219.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601053608889219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828631.EUR","LU0572944931.SGD","LU1188198961.HKD","BK4505","NIO.SI","LU0348767384.USD","601633","BK1608","LU0327786744.USD","BK1591","BK4504","BK4509","LU0051755006.USD","LU0320764599.SGD","LU0326950275.SGD","LU1303224171.USD","02333","LU1794554557.SGD","BK4581","BK1615","BK4585","09999","LU0593848301.USD","LU2097828557.USD","BK4548","BK1588","81024","LU0348766576.USD","LU2097828474.EUR","09866","NTES","LU2097828805.USD","GWLLY","BK4532","LU0210526637.USD","BK1095","LU0708995583.HKD","LU1023057109.AUD","LU0211977185.USD","BK4526","LU0359201885.HKD","KSTmain","BK1119","LU0463099449.HKD","LU1719994722.HKD","LU0359201612.USD","LU0588546209.SGD","BK4574","BK1575","LU2097828714.EUR","BK4534","BK4531","LU0359202008.SGD","BK4099","BK4555","BK4588","LU0307460666.USD","01024","LU1251922891.USD","NIO","LU0456827905.SGD","BK1590","09995","BK1610","LU0052750758.USD","EVS.SI","LU0244354667.USD","688331","LU1720050803.USD","LU0140636845.USD","LU1770034418.SGD"],"gpt_icon":1},{"id":"2601003478","title":"港股荣昌生物午后涨近8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601003478","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601003478?lang=zh_cn&edition=full","pubTime":"2026-01-05 15:06","pubTimestamp":1767596799,"startTime":"0","endTime":"0","summary":"每经AI快讯，荣昌生物(09995.HK)午后涨近8%，截至发稿涨7.67%，报79.3港元，成交额4.05亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601053608737829.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601053608737829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","BK0239","BK1161","09995","LU1064130708.USD","688331","BK1574","BK1583","LU2148510915.USD","LU1064131003.USD","LU2488822045.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2601080330","title":"港股异动 | 荣昌生物(09995)午后涨近8% 维迪西妥单抗新适应症拟纳入突破性疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2601080330","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601080330?lang=zh_cn&edition=full","pubTime":"2026-01-05 14:50","pubTimestamp":1767595850,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物午后涨近8%，截至发稿，涨7.67%，报79.3港元，成交额4.05亿港元。消息面上，2025年12月31日，CDE官网显示，荣昌生物维迪西妥单抗新适应症拟纳入突破性治疗品种，联合曲妥珠单抗及特瑞普利单抗一线治疗HER2高表达的晚期胃/胃食管结合部腺癌。此前维迪西妥单抗已经有3次纳入突破性治疗，若是此次通过公示，将成为该药物的第4次突破性疗法认定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064130708.USD","BK1161","09995","BK1574","688331","LU1064131003.USD","LU2488822045.USD","LU1969619763.USD","LU2148510915.USD","LU2328871848.SGD","BK1583","BK0239"],"gpt_icon":0},{"id":"2595866467","title":"荣昌生物（688331）披露2022年及2023年A股限制性股票激励计划归属条件成就公告，12月29日股价下跌0.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595866467","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595866467?lang=zh_cn&edition=full","pubTime":"2025-12-29 17:37","pubTimestamp":1767001039,"startTime":"0","endTime":"0","summary":"截至2025年12月29日收盘，荣昌生物报收于78.75元，较前一交易日下跌0.48%，最新总市值为443.92亿元。该股当日开盘79.3元，最高80.53元，最低78.5元，成交额达3.38亿元，换手率为2.63%。公司近日发布公告称，第二届董事会第三十三次会议审议通过多项议案。此外，董事会认为2023年A股限制性股票激励计划首次授予第一个归属期的归属条件已达成，同意办理归属，并作废该计划中部分离职激励对象已获授但尚未归属的限制性股票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900023766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688331","LU1969619763.USD","BK0239","399300","BK1574","BK1583","LU1064131003.USD","LU2148510915.USD","159982","LU1064130708.USD","LU2488822045.USD","LU2328871848.SGD","09995"],"gpt_icon":0},{"id":"2594147241","title":"每周股票复盘：荣昌生物（688331）拟回购2000万至4000万元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2594147241","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594147241?lang=zh_cn&edition=full","pubTime":"2025-12-28 01:48","pubTimestamp":1766857693,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，荣昌生物报收于79.13元，较上周的82.4元下跌3.97%。本周，荣昌生物12月22日盘中最高价报82.79元。本周关注点公司公告汇总：荣昌生物计划以集中竞价方式回购股份，金额不低于2000万元且不超过4000万元。公司公告汇总：本次回购股份价格不超过95元/股，期限为董事会审议通过之日起12个月内。本次回购股份拟用于员工持股计划或股权激励，若3年内未使用完毕，未使用部分将注销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","LU1064131003.USD","LU2488822045.USD","688331","BK0239","BK1161","09995","LU1064130708.USD","BK1574","LU2148510915.USD","BK1583","LU2328871848.SGD"],"gpt_icon":0},{"id":"2594287939","title":"光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事","url":"https://stock-news.laohu8.com/highlight/detail?id=2594287939","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594287939?lang=zh_cn&edition=full","pubTime":"2025-12-25 14:21","pubTimestamp":1766643688,"startTime":"0","endTime":"0","summary":"今年创新药企业频繁宣布BD交易，但从三季度以来，原本利好的消息却不被二级市场买账。最近一周，BD交易再掀一个小高潮。12月22日，先声药业（02096.HK）宣布其附属公司江苏再明与Ipsen于12月19日签订独家授权许可协议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601825588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","002755","000661","02096","01801","02142","688428","LU2097828557.USD","LU2097828631.EUR","LU2580892862.HKD","LU1969619763.USD","09995","03692","LU0502904849.HKD","BK1589","BK0057","LU1328615791.USD","LU1064131003.USD","LU0405327494.USD","LU0405327148.USD","LU2488822045.USD","BK0028","LU1997245177.USD","LU1064130708.USD","LU1997244956.HKD","LU2097828474.EUR","BK1161","603087","LU2148510915.USD","BK0188","02509","BK0060","688062","BK1593","688336","LU2495084118.USD","688331","01530","LU1997245094.SGD","LU2097828714.EUR","600276","LU1781817850.SGD","LU1146622755.USD","06978","BK1574","LU2097828805.USD","BK0012","BK0239","BK0196","01167"],"gpt_icon":0},{"id":"2593245061","title":"荣昌生物(09995.HK)涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593245061","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593245061?lang=zh_cn&edition=full","pubTime":"2025-12-23 10:13","pubTimestamp":1766456035,"startTime":"0","endTime":"0","summary":"每经AI快讯，荣昌生物(09995.HK)涨超3%，截至发稿涨3.41%，报78.8港元，成交额9838.12万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512233599267548.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512233599267548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064130708.USD","BK1161","09995","BK1574","688331","LU1064131003.USD","LU2488822045.USD","LU1969619763.USD","LU2148510915.USD","LU2328871848.SGD","BK1583","BK0239"],"gpt_icon":0},{"id":"2593457234","title":"港股异动 | 荣昌生物(09995)涨超3% 自研RC148实现双路径突破 机构看好后续临床潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2593457234","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593457234?lang=zh_cn&edition=full","pubTime":"2025-12-23 10:02","pubTimestamp":1766455373,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物涨超3%，截至发稿，涨3.41%，报78.8港元，成交额9838.12万港元。研究数据显示，RC148单药与联合方案均显示出突出的临床疗效和可控的安全性，实现了双路径突破。目前公司正在积极推进相关临床：根据公司投资者调研纪要，RC148联合治疗一线非小细胞肺癌的II期临床试验已完成患者入组并计划启动联合治疗非小细胞肺癌的Ⅲ期临床研究，看好后续临床潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384748.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","688331","LU1969619763.USD","BK1574","BK0239","LU1064131003.USD","BK1583","LU2148510915.USD","LU1064130708.USD","LU2488822045.USD","LU2328871848.SGD","09995"],"gpt_icon":0},{"id":"2593483499","title":"荣昌生物拟回购 金额2000万元至4000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593483499","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593483499?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:21","pubTimestamp":1766395284,"startTime":"0","endTime":"0","summary":"12月22日，荣昌生物（688331/09995）发布公告，计划以集中竞价交易方式回购股份，回购金额不低于2000万元且不超过4000万元，回购价格上限为95元/股，回购股份将用于员工持股计划或股权激励，回购期限为自董事会审议通过之日起12个月内。2025年前三季度，荣昌生物实现收入17.20亿元，归母净利润-5.51亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512223598357980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","09995","LU1064130708.USD","BK1574","LU2488822045.USD","BK1161","LU1064131003.USD","BK0239","LU1969619763.USD","688331","LU2328871848.SGD","LU2148510915.USD"],"gpt_icon":0},{"id":"2593483856","title":"获阿斯利康20亿美元重金押注，加科思泛KRAS靶向药成功出海，股价为何不涨反跌？","url":"https://stock-news.laohu8.com/highlight/detail?id=2593483856","media":"时代财经","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593483856?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:58","pubTimestamp":1766393880,"startTime":"0","endTime":"0","summary":"12月21日晚间，加科思药业（01167.HK）宣布，已就其自主研发的泛KRAS（Pan-KRAS）抑制剂 JAB-23E73与阿斯利康（AZN.US）达成合作协议。根据协议，阿斯利康将获得该产品在中国以外市场的独家 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251222/c673401182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["LU2148510915.USD","688235","688331","LU2488822045.USD","LU1064131003.USD","LU1064130708.USD","688428","BK0239"],"gpt_icon":0},{"id":"2592903581","title":"荣昌生物：关于取得金融机构股票回购专项贷款承诺函的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2592903581","media":"证券日报","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592903581?lang=zh_cn&edition=full","pubTime":"2025-12-18 20:07","pubTimestamp":1766059669,"startTime":"0","endTime":"0","summary":"证券日报网讯12月18日晚间，荣昌生物发布公告称，近日，公司取得招商银行股份有限公司烟台分行出具的《贷款承诺函》，主要内容如下：1、贷款承诺额度：不超过人民币3600万元且不超过实际回购金额的90%；2、贷款期限：不超过36个月；3、贷款用途：专项用于回购公司股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512183595657981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","LU1064130708.USD","LU1064131003.USD","LU1969619763.USD","BK1583","FISI","688331","BK4211","09995","LU2148510915.USD","BK1574","BK1161","LU2488822045.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2591641505","title":"荣昌生物：第二届董事会第三十二次会议决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2591641505","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591641505?lang=zh_cn&edition=full","pubTime":"2025-12-15 21:05","pubTimestamp":1765803918,"startTime":"0","endTime":"0","summary":"证券日报网讯12月15日晚间，荣昌生物发布公告称，公司第二届董事会第三十二次会议审议通过《关于以集中竞价交易方式回购公司股份方案的议案》等多项议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153591974866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2148510915.USD","BK1574","LU2328871848.SGD","LU1969619763.USD","09995","688331","LU2488822045.USD","LU1064131003.USD","BK1161","LU1064130708.USD","BK0239","BK1583"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768227429058,"stockEarnings":[{"period":"1week","weight":0.2464},{"period":"1month","weight":0.119},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.4917},{"period":"1year","weight":2.7831},{"period":"ytd","weight":0.2464}],"compareEarnings":[{"period":"1week","weight":0.0382},{"period":"1month","weight":0.0564},{"period":"3month","weight":0.0573},{"period":"6month","weight":0.1739},{"period":"1year","weight":0.2831},{"period":"ytd","weight":0.0382}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"荣昌生物制药(烟台)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15248人(较上一季度增加18.39%)","perCapita":"10645股","listingDate":"2022-03-31","address":"山东省烟台市福山区中国(山东)自由贸易试验区烟台片区烟台开发区北京中路58号","registeredCapital":"56371万元","survey":" 荣昌生物制药(烟台)股份有限公司的主营业务是抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物的研发、生产和销售。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC88、RC148、RC278、RC288。泰它西普发明专利先后获得中国、美国、欧洲等国家和地区的授权，得到了国家“十一五”、“十二五”、“十三五”期间“重大新药创制”科技重大专项支持。","listedPrice":48},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,688331,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}